Process Induced Protein Aggregation

血浆是生物技术工业中治疗性蛋白质的宝贵来源。已经开发了商业规模的方法来从血浆中分离蛋白质。目前的泵送和过滤操作导致产品的不稳定和聚集。这项研究计划将使用新的流变荧光和微流控方法来确定诱导有害蛋白质聚集的临界流动和溶液条件。开发的知识将用于评估CSL Bioplasma在血液处理中使用的不同单元操作的效果，以提高工艺效率，减少产品损失并提高产品质量。澳大利亚在生物技术方面的国际竞争力将得到提升。

Blood plasma is a valuable source of therapeutic proteins for the biotechnology industry. Commercial scale processes have been developed to separate the proteins from plasma. Current pumping and filtering operations cause instability and aggregation in the products. This research programme will use novel rheofluorescence and microfluidic methods to identify critical flow and solution conditions that induce deleterious protein aggregation. The knowledge developed will be used to assess the effects of different unit operations used by CSL Bioplasma in blood processing to improve process efficiency, reduce product loss and improve product quality. Australia's international competitiveness in biotechnology will be advanced.